-- 根據週四在東京證券交易所發布的公告，杏林製藥（TYO:4569）將與大東製藥（TYO:4577）及其合作夥伴簽署諒解備忘錄，將其仿製藥業務轉讓給新藥研發企業，以期將業務重心轉向新藥研發。 杏林製藥計畫將其子公司杏林瑞美迪奧（Kyorin Remedio）及其相關生產設施轉讓給由大東製藥及其聯合投資者共同設立的新平台公司，旨在保障日本仿製藥市場的穩定供應。 公司此舉旨在優先發展新藥研發，同時應對仿製藥產業面臨的結構性挑戰，例如獲利能力不足和供應中斷等問題。 杏林製藥預計9月簽署最終協議，並計畫於2027年4月完成業務轉讓。
Related Articles
Japan
US 10-Year Treasury Yield Leans Higher at 4.32% Pre-Bell; 2-Year Rate Climbs 1.3 Basis Points to 3.79%
Japan
CGI Launching High-security Sovereign AI Platform in Finland For Enterprise and Public Sector Use
$GIB-A.TO
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE